신경내분비종양 치료 시장 규모, 점유율, 성장 분석(종양 유형별, 치료 제품별, 부위별, 최종 용도별, 지역별) : 산업 예측(2025-2032년)
Neuroendocrine Tumors Treatment Market Size, Share, Growth Analysis, By Tumor Types (Meningiomas, Adrenal Cancer), By Treatment Products (Somatostatin Analogs (SSAs), Targeted Therapy), By Sites, By End Uses, By Region - Industry Forecast 2025-2032
상품코드:1623976
리서치사:SkyQuest Technology Consulting Pvt. Ltd.
발행일:2025년 01월
페이지 정보:영문 165 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계 신경내분비종양 치료 시장 규모는 2023년 23억 4,000만 달러로 평가되며, 2024년 24억 8,000만 달러에서 2032년 38억 9,000만 달러로 성장할 것으로 예상되며, 예측 기간(2025-2032년) 동안 5.8%의 CAGR을 기록할 것으로 예상됩니다.
전 세계적으로 암 발병률의 증가, 특히 카르티노이드 종양과 같은 신경내분비종양(NET)의 증가는 혁신적인 치료법이 시급히 필요하다는 것을 강조하고 있습니다. 신경계와 내분비계 모두에서 발생하는 이 희귀 종양은 주로 소화관을 침범하지만 맹장, 췌장, 직장, 폐와 같은 기관에서도 발견됩니다. 위장 문제부터 심장 문제까지 다양한 증상이 NET의 복잡성을 강조하고 있습니다. 신경내분비종양 치료 시장은 진단 능력의 향상과 R&D 투자 증가와 함께 인지도가 높아짐에 따라 크게 성장할 것으로 예상됩니다. 이러한 추세는 예측 기간 동안 새로운 치료법의 도입과 탐지 방법의 개선을 통해 희귀 악성 종양에 대한 노력이 확대되고 있음을 보여줍니다.
목차
소개
분석 목적
시장 범위
정의
분석 방법
정보 조달
2차·1차 데이터 방법
시장 규모 예측
시장 상정과 제약
주요 요약
시장 개요와 전망
수급 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porters 분석
시장의 주요 인사이트
주요 성공요인
경쟁 정도
주요 투자 기회
시장 생태계
시장 매력도 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
기술 분석
규제 분석
특허 분석
사례 연구
세계의 신경내분비종양 치료 시장 규모·CAGR : 종양 종류별(2025-2032년)
시장 개요
수막종
부신암
카르시노이드 종양
부신경절종
갈색 세포종
기타
세계의 신경내분비종양 치료 시장 규모·CAGR : 치료 제품별(2025-2032년)
시장 개요
소마트스타틴 유사체(SSA)
표적요법
기타
세계의 신경내분비종양 치료 시장 규모·CAGR : 부위별(2025-2032년)
시장 개요
폐
췌장
결장
소장
직장
위
기타
세계의 신경내분비종양 치료 시장 규모·CAGR : 최종 용도별(2025-2032년)
시장 개요
병원
클리닉
기타
세계의 신경내분비종양 치료 시장 규모·CAGR(2025-2032년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 구도
상위 5개사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 기업이 채용한 전략
시장의 최근 동향
주요 기업의 시장 점유율(2024년)
주요 기업 개요
기업 개요
제품 포트폴리오 분석
부문별 점유율 분석
매출 전년비 비교(2022-2024년)
주요 기업 개요
Novartis AG(스위스)
Bristol Myers Squibb Company(미국)
Pfizer Inc.(미국)
Boehringer Ingelheim International GmbH(독일)
Hutchison MediPharma Limited(중국)
AVEO Pharmaceuticals, Inc.(미국)
Ipsen Pharma(프랑스)
Eli Lilly and Company(미국)
Exelixis, Inc.(미국)
Jubilant Pharmova Limited(인도)
F. Hoffmann-La Roche Ltd(스위스)
Viatris Inc.(미국)
Thermo Fisher Scientific Inc.(미국)
Regeneron Pharmaceuticals, Inc.(미국)
Sun Pharmaceutical Industries Ltd.(인도)
Teva Pharmaceutical Industries Ltd.(이스라엘)
Lupin(인도)
Exact Sciences Corporation(미국)
Advanced Accelerator Applications(프랑스)
BioSynthema Inc.(미국)
결론과 추천사항
ksm
영문 목차
영문목차
Global Neuroendocrine Tumors Treatment Market size was valued at USD 2.34 billion in 2023 and is poised to grow from USD 2.48 billion in 2024 to USD 3.89 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).
The global rise in cancer incidence, particularly neuroendocrine tumors (NET) such as carcinoid tumors, underscores an urgent need for innovative treatments. These rare tumors, originating from both the neurological and endocrine systems, primarily affect the gastrointestinal tract but are also found in organs like the appendix, pancreas, rectum, and lungs. Symptoms ranging from gastrointestinal issues to heart problems highlight the complexity of NETs. As awareness increases, coupled with enhanced diagnostic capabilities and rising research and development investments, the treatment market for neuroendocrine tumors is poised for significant growth. This trend is indicative of a broader commitment to addressing rare malignancies through the introduction of new therapies and improved detection methods over the forecast period.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neuroendocrine Tumors Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Neuroendocrine Tumors Treatment Market Segmental Analysis
Global Neuroendocrine Tumors Treatment Market is segmented by Tumor Types, Treatment Products, Sites, End Uses and region. Based on Tumor Types, the market is segmented into Meningiomas, Adrenal Cancer, Carcinoid Tumors, Paraganglioma, Pheochromocytoma and Others. Based on Treatment Products, the market is segmented into Somatostatin Analogs (SSAs), Targeted Therapy and Others. Based on Sites, the market is segmented into Lung, Pancreas, Colon, Small Intestine, Rectum, Stomach and Others. Based on End Uses, the market is segmented into Hospitals, Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Neuroendocrine Tumors Treatment Market
The Global Neuroendocrine Tumors Treatment market is poised for growth due to the increasing incidence of neuroendocrine tumors (NET) around the world. Data from the American Society of Clinical Oncology (ASCO) indicates a steady rise in both the incidence and prevalence of these tumors, which significantly influences market dynamics. As more individuals are diagnosed with this rare condition, there is a corresponding increase in the adoption of various treatment medications, thereby further propelling market demand. This trend reflects a growing recognition of neuroendocrine tumors, leading to advancements in treatment options and an overall expansion of the market.
Restraints in the Global Neuroendocrine Tumors Treatment Market
The Global Neuroendocrine Tumors (NET) Treatment market faces several restraints that could limit its growth. One significant factor is the potential side effects associated with treatments, which may deter patients from pursuing therapy. Common adverse effects include elevated blood sugar levels, gallstone formation, and mild digestive issues such as bloating and nausea. Additionally, the high costs associated with developing effective treatments and pharmaceuticals can pose a substantial barrier to market expansion. As a result, these financial burdens and the apprehension surrounding treatment-related complications may impede the overall progress of the NET treatment market during the forecast period.
Market Trends of the Global Neuroendocrine Tumors Treatment Market
The global neuroendocrine tumors treatment market is witnessing a significant upward trend, primarily driven by the increasing adoption of somatostatin analogs (SSAs). As these therapeutic agents effectively inhibit tumor growth, alleviate symptoms, and improve biomarker profiles, they have emerged as the preferred choice for managing neuroendocrine tumors. Their proven safety and efficacy contribute to dominating the revenue share in the market. Additionally, ongoing clinical trials and potential approvals of newer SSAs are expected to further fuel market growth. The landscape is evolving, with rising patient awareness and advancements in treatment protocols, making it a promising arena for stakeholders in the healthcare sector.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Regulatory Analysis
Patent Analysis
Case Studies
Global Neuroendocrine Tumors Treatment Market Size by Tumor Types & CAGR (2025-2032)
Market Overview
Meningiomas
Adrenal Cancer
Carcinoid Tumors
Paraganglioma
Pheochromocytoma
Others
Global Neuroendocrine Tumors Treatment Market Size by Treatment Products & CAGR (2025-2032)
Market Overview
Somatostatin Analogs (SSAs)
Targeted Therapy
Others
Global Neuroendocrine Tumors Treatment Market Size by Sites & CAGR (2025-2032)
Market Overview
Lung
Pancreas
Colon
Small Intestine
Rectum
Stomach
Others
Global Neuroendocrine Tumors Treatment Market Size by End Uses & CAGR (2025-2032)
Market Overview
Hospitals
Clinics
Others
Global Neuroendocrine Tumors Treatment Market Size & CAGR (2025-2032)
North America (Tumor Types, Treatment Products, Sites, End Uses)
US
Canada
Europe (Tumor Types, Treatment Products, Sites, End Uses)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Tumor Types, Treatment Products, Sites, End Uses)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Tumor Types, Treatment Products, Sites, End Uses)
Brazil
Rest of Latin America
Middle East & Africa (Tumor Types, Treatment Products, Sites, End Uses)
